Methods for treating cancer using...

Details Methods for treating cancer using... Methods for treating cancer using...

2005-11-04

2010-11-16

Andres, Janet L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S201000

Reexamination Certificate

active

07834033

ABSTRACT:
Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group, which may be further substituted in the 5-position with alkyl or halogeno, and in the 4-position with alkyl or a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα. A typical embodiment is 2-(2,6-dioxo-3-hydroxy-5-fluoro-piperidin-5-yl)4-aminoisoindolin-1-one.

REFERENCES:
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 5998438 (1999-12-01), Slassi et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 6762195 (2004-07-01), Muller et al.
patent: 6977268 (2005-12-01), D'Amato
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge
patent: 2003/0096841 (2003-05-01), Robarge
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldi
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0127545 (2004-07-01), D'Amato et al.
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 2004/0220144 (2004-11-01), Zeldis
patent: 2005/0096351 (2005-05-01), Jaworsky et al.
patent: 2005/0100529 (2005-05-01), Zeldis
patent: 2005/0143344 (2005-06-01), Zeldis et al.
patent: 2005/0143420 (2005-06-01), Moutouh et al.
patent: 2005/0203142 (2005-09-01), Zeldis et al.
patent: 2005/0214328 (2005-09-01), Zeldis et al.
patent: 2005/0222209 (2005-10-01), Zeldis et al.
patent: WO 94/20085 (1994-09-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/019649 (1998-05-01), None
patent: WO 98/54170 (1998-12-01), None
Corral et al., 1999, “Immunomodulation by thalidomide and thalidomide analogues,”Ann. Rheum. Dis.58:(Suppl I):1107-1113.
Dibbs et al., 1998, “Thalidomide and thalidomide analogs suppress TN-alpha secretion by myocytes,”Circulation98(17 Suppl), Abstract 1284):1247.
He et al., 1993, “Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease,” 206th American Chemical Society, Chicago, IL;Med. Chem.paper 216.
U.S. Appl. No. 09/287,377, filed Apr. 7, 1999, D'Amato.
Jonsson, 1972, “Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues,”Acta Pharm. Suec.9(6):521-542.
Muller et al., 1999, “Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production,”Bioorg. Med. Chem. Lett.9(11):1625-1630.
Muller et al., 1996, “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity,”J. Med. Chem.39(17):3238-3240.
Muller et al., 1998, “Thalidomide analogs and PDE4 inhibition,”Bioorg. Med. Chem. Lett.8(19):2669-2674.
Shire et al., 1998, “TNF-alpha inhibitors and rheumatoid arthritis,”Exp. Opin. Ther. Patents8(5):531-544.
Wolff, ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5thed:172-178, 949-982.
Luzzio et al., Jan. 15, 2000, “Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-gamma-hydroxyglutamic acid,”Tetra. Lett.41:2275-2278.
Luzzio et al., Jul. 12, 2000, “Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S, 3S (3-hydroxy) ornithine,”Tetra. Lett.41:7151-7155.
Teubert et al., 1998, “5′-Substituted thalidomide analogs as modulators of TNF-alpha,”Arch. Pharm. Med. Chem.331(1):7-12.
“Namalwa” http://www.copewithcytokines.de/cope.cgi?key=Namalwa, Jan. 2002.
“Biological Therapies: Using the Immune System to Treat Cancer” http://cancerweb.ncl.ac.uk/cancernet/600072.html, Jan. 2001.
Schaffer, P.H. et al, Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immuniomodulatory Drugs. The Journal of Pharacology and Experimental Therapeutics (2003) vol. 305. No. 3. pp. 1222-1232.

Affiliated with

Also associated with

Rating

Methods for treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4180607